



Sheet 1 of 4

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50291/004002
	Serial No.	10/825,958
	Applicant	Robert Chalifour et al.
	Filing Date	April 16, 2004
	Group	1614 1649
	IDS Filed	March 7, 2005

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
KAB	4,116,768	09/26/1978	Isowa et al.			
	5,002,872	03/26/1991	Gross			
	5,470,951	11/28/1995	Roberts			
	5,514,548	05/07/1996	Krebber et al.			
	5,652,334	07/29/1997	Roberts			
	5,688,651	11/18/1997	Solomon			
	5,721,130	02/24/1998	Seubert et al.			
	5,753,624	05/19/1998	McMichael et al.			
	5,837,672	11/17/1998	Schenk et al.			
	5,851,996	12/22/1998	Kline			
	5,854,204	12/29/1998	Findeis et al.			
	5,869,093	02/09/1999	Weiner et al.			
	5,891,991	04/06/1999	Wasco et al.			
	5,985,242	11/16/1999	Findeis et al.			
↓	6,261,569	07/17/2001	Comis et al.			
KAB	10/895,646	Filed 07/21/2004	Chalifour et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
KAB	94/05311	03/17/1994	WO			
KAB	95/05393	02/23/1995	WO			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50291/004002
		Serial No.	10/825,958
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Robert Challfour et al.
		Filing Date	April 16, 2004
		Group	1014 1649
		IDS Filed	March 7, 2005
(37 C.F.R. § 1.98(b))			

KAB	95/05849	03/02/1995	WO			
	95/08999	04/06/1995	WO			
	95/12815	05/11/1995	WO			
	95/23166	08/31/1995	WO			
	95/31996	11/30/1995	WO			
	96/13583	05/09/1996	WO			
	96/28471	09/19/1996	WO			
	96/37621	11/28/1996	WO			
	97/08320	03/06/1997	WO			
	97/21728	06/19/1997	WO			
	97/32017	09/04/1997	WO			
	98/02462	01/22/1998	WO			
	98/05350	02/12/1998	WO			
	98/08868	03/05/1998	WO			
	98/22120	05/28/1998	WO			
	99/06587	02/11/1999	WO			
	99/27944	06/10/1999	WO			
	99/27949	06/10/1999	WO			
	99/58564	11/18/1999	WO			
	99/60021	11/25/1999	WO			
	99/60024	11/25/1999	WO			
↓	00/20027	04/13/2000	WO			
KAB	00/26238	05/11/2000	WO			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50291/004002
	Serial No.	10/825,958
	Applicant	Robert Chalifour et al.
	Filing Date	April 16, 2004
	Group	1014 1649
	IDS Filed	March 7, 2005

KAB	00/43039	07/27/2000	WO			
KAB	00/68263	11/16/2000	WO			
KAB	0752886 B1	01/28/1998	EP			
KAB	199870091	07/30/1998	AU			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
KAB	Alberts, Molecular Biology of the Cell, Garland Publishing, page 54, 1989.					
	Bard et al., "Peripherally Administered Antibodies Against Amyloid Beta-Peptide Enter the Central Nervous System and Reduce Pathology in a Mouse Model of Alzheimer Disease," Nat. Med. 6(8):916-919, 2000.					
	Benkirane et al., "Antigenicity and Immunogenicity of Modified Synthetic Peptides Containing D-Amino Acid Residues," J. Biol. Chem. 268(23):26279-26285, 1993.					
	DeMattos et al., "Peripheral Anti-ABeta Antibody Alters CNS and Plasma ABeta Clearance and Decreases Brain ABeta Burden in a Mouse Model of Alzheimer's Disease," Proc. Natl. Acad. Sci. USA (pub ahead of print) , 2001,					
	Findeis et al., "Modified Peptide Inhibitors of Amyloid Beta-Peptide Polymerization," Biochemistry 38:6791-6800, 1999.					
	Flood et al., "Topography of a Binding Site for Small Amnesic Peptides Deduced from Structure-Activity Studies: Relation to Amnesic Affect of Amyloid Beta Protein," Proc. Natl. Acad. Sci. USA 91:380-384, 1994.					
	Frenkel, "Generation of Auto-Antibodies Towards Alzheimer's Disease Vaccination," Vaccine 19(17-19):2615-2619, 2001.					
	Frenkel, "Immunization Against Alzheimer's Beta-Amyloid Plaques Via EFRH Phage Administration," Proc. Natl. Acad. Sci. USA 97(21):11455-11459, 2000.					
	Giulian, "The HHQK Domain of Beta-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," J. Biol. Chem. 273(45):29719-29726, 1998.					
	Morgan et al., "A Beta Peptide Vaccination Prevents Memory Loss in an Animal Model of Alzheimer's Disease," Nature 408(6815):982-985, 2000.					
	Pearson et al., "Beta Peptide Immunization Reduces Behavioral Impairment and Plaques in a Model of Alzheimer's Disease," Nature 408(6815):979-982, 2000.					
	Schenk et al., "Immunization with Amyloid-Beta Attenuates Alzheimer's-Disease-Like Pathology in the PDAPP Mouse," Nature 400(6740):173-177, 1999.					
	Sela et al., "Different Roles of D-Amino Acids in Immune Phenomena," FASEB J. 11(6):449-456, 1997.					
	Soto et al., "Inhibition of Alzheimer's Amyloidosis by Peptides that Prevent Beta-Sheet Conformation," Biochem. Biophys. Res. Comm. 226(3):672-680, 1996.					
✓	Tjernberg et al., "Arrest of Beta-Amyloid Fibril Formation by a Pentapeptide Ligand," J. Biol. Chem. 271(15):8545-8548, 1996.					
KAB	Tjernberg et al., "Controlling Amyloid Beta-Peptide Fibril Formation with Protease-Stable Ligands," J. Biol. Chem. 272(19):12601-12605, 1997.					

98:8850-
8855.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



Sheet 1 of 1

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Attorney Docket No.

50291/004002

Serial No.

10/825,958

Applicant

R. Chalifour et al.

Filing Date

April 16, 2004

Group

~~1644~~ 1649

IDS Filed

May 6, 2005

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

(37 C.F.R. § 1.98(b))

U.S. PATENT DOCUMENTS

Examiner's Initials	Document Number	Issue or Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
KAB	6,710,226	3/23/04	Schenk			
	6,743,427	6/1/04	Schenk			
	6,750,324	6/15/04	Schenk et al.			
	6,761,888	7/13/04	Schenk			
	6,787,138	9/7/04	Schenk			
	6,787,139	9/7/04	Schenk			
	6,787,140	9/7/04	Schenk			
	6,787,143	9/7/04	Schenk			
	6,787,144	9/7/04	Schenk			
	6,787,523	9/7/04	Schenk			
	6,787,637	9/7/04	Schenk			
	6,808,712	10/26/04	Schenk			
	6,818,218	11/16/04	Schenk			
	6,866,849	3/15/05	Schenk			
↓	6,866,850	3/15/05	Schenk			
KAB	6,875,434	4/5/05	Schenk			

EXAMINER /Kimberly Ballard/

DATE CONSIDERED 06/01/2006

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.



SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50291/004002 Serial No. 10/825,958 Applicant Robert Chalifour et al. Filing Date April 16, 2004 Group 1649 IDS Filed April 24, 2006		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)						
(37 C.F.R. § 1.98(b))						
U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Issue or Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
KAB	6,022,859	02/08/00	Kiessling et al.			
KAB	6,331,440	12/18/01	Nordstedt et al.			
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
KAB	00/72880	12/07/00	WIPO			
KAB	01/39796	06/07/01	WIPO			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
KAB	Chen et al., "Neurodegenerative Alzheimer-Like Pathology in PDAPP 717V→F Transgenic Mice," Prog. in Brain Res. 117:327-334, 1998.					
KAB	Cribbs et al., "All-D-Enantiomers of Beta-Amyloid Exhibit Similar Biological Properties to All-L-Beta-Amyloids," J. Biol. Chem. 272:7431-7436, 1997.					
KAB	Games et al., "Alzheimer-Type Neuropathology in Transgenic Mice Overexpressing V717F Beta-Amyloid Precursor Protein," Nature 373(6514):523-527, 1995.					
KAB	Jobling et al., "Analysis of Structure and Function of the B Subunit of Cholera Toxin by the Use of Site-Directed Mutagenesis," Mol. Microbiol. 5(7):1755-1767, 1991.					
KAB	Lemere et al., "Mucosal Administration of Aβ Peptide Decreases Cerebral Amyloid Burden in PD-APP Transgenic Mice," Society for Neuroscience Abstracts, vol. 25, part 1, Abstract 519.6, 29 th Annual Meeting 10/23-10/28, 1999.					
KAB	Münch et al., "Potential Neurotoxic Inflammatory Responses to Aβ Vaccination in Humans," J. Neural Transmission 109(7-8):1081-1087, 2002.					
KAB	Skolnick et al., "From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era," Trends in Biotech. 18(1):34-39, 2000.					
EXAMINER /Kimberly Ballard/			DATE CONSIDERED 06/01/2006			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						